companydirectorylist.com  Global Business Directories and Company Directories
Search Business,Company,Industry :


Country Lists
USA Company Directories
Canada Business Lists
Australia Business Directories
France Company Lists
Italy Company Lists
Spain Company Directories
Switzerland Business Lists
Austria Company Directories
Belgium Business Directories
Hong Kong Company Lists
China Business Lists
Taiwan Company Lists
United Arab Emirates Company Directories


Industry Catalogs
USA Industry Directories












Company Directories & Business Directories

BANKE PERFORMANCE & ENGNRNG

FELTON-USA

Company Name:
Corporate Name:
BANKE PERFORMANCE & ENGNRNG
Company Title:  
Company Description:  
Keywords to Search:  
Company Address: 1670 Mclellan Rd,FELTON,CA,USA 
ZIP Code:
Postal Code:
95018-9545 
Telephone Number:  
Fax Number: 8313351422 (+1-831-335-1422) 
Website:
 
Email:
 
USA SIC Code(Standard Industrial Classification Code):
769999 
USA SIC Description:
Repair Shops & Related Services Nec 
Number of Employees:
 
Sales Amount:
 
Credit History:
Credit Report:
 
Contact Person:
 
Remove my name



copy and paste this google map to your website or blog!

Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example, Blogger Example)









Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer

(Any information to deal,buy, sell, quote for products or service)

Your Subject:
Your Comment or Review:
Security Code:



Previous company profile:
FALL CREEK CONSULTANTS
MEAN FAIRY PRODUCTIONS
WABBIT SOFTWARE
Next company profile:
company
NEW VIEW PHOTOGRAPHY
GREY MATTER PRODUCTIONS










Company News:
  • Frontline treatment options for higher-risk MDS: can we move . . .
    FUSION-AML-001 (MDS Cohort) 2 azacitidine + durvalumab (1500 mg IV q 4 weeks) azacitidine Int to very high MDS IPSS-R int to very high ORR (CR, mCR, HI) 61 9% vs 47 6% (P = 0 18) No Increase PDL1 on BM Blasts 29 SUPPORT 3 azacitidine + eltrombopag (200 mg day, up to 300 mg day) azacitidine Int to HR-MDS
  • Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS
    We analyzed data from adult patients with low- or intermediate-1–risk MDS or chronic myelomonocytic leukemia, as measured by the International Prognostic Scoring System, who had been enrolled in a randomized phase 2 study of low-dose decitabine versus low-dose azacitidine; the description of trial methods and results with follow-up of x-years has been previously published 8 Briefly
  • Successful long-term treatment with azacitidine in patient . . .
    Several studies and clinical trials tested efficacy of both azacitidine and decitabine and they revealed overall response rates in the range of 30-60% and a median Overall Survival (OS) between 12 to 37 months 3,4,11,12 Based on latest findings, azacitidine was licensed for non-proliferative CMML-2, whereas there are limited data for
  • Comparison between 5-day decitabine and 7-day azacitidine for . . .
    In higher-risk MDS, a 7-day azacitidine regimen (75 mg m 2 daily every 4 weeks) was reported to result in higher response rates and better overall survival (OS) outcomes than treatment with
  • Efficacy of azacitidine is independent of molecular and . . .
    Azacitidine is the first drug to demonstrate a survival benefit for patients with MDS However, only half of patients respond and almost all patients eventually relapse Limited and conflicting data are available on predictive factors influencing response We analyzed 128 patients from two instituti …
  • 5-azacitidine prolongs overall survival in patients with . . .
    In a number of phase 2 trials 5-azacitidine and decitabine given to patients with MDS resulted in an overall response rate of 50% 5 – 8 This led to the initiation of phase 3 trials comparing 5-azacitidine or decitabine to best supportive care
  • Combination Therapy Shows Promising Results in Some Higher . . .
    “All the signals of activity go in the same direction, which is always encouraging with a drug,” Dr Sekeres says Efficacy results were strongest in the higher-risk MDS group, with a significant improvement in event-free survival among the cohort receiving the combination therapy compared with azacitidine alone (20 2 months vs 14 8 months), and in overall survival (23 9 months vs 19 1
  • Vidaza® Improves Survival in Myelodysplastic Syndromes
    Vidaza was the first agent approved for the treatment of MDS in 2004 It applies its anticancer effects by targeting aspects of expression of DNA, ultimately killing cancer cells Vidaza has demonstrated the ability to reduce or prevent the need for blood transfusions in MDS; however, its effects on survival have not been clearly established




Business Directories,Company Directories
Business Directories,Company Directories copyright ©2005-2012 
disclaimer